Lenvatinib (off Label)
Lenvima
Sources
fda, as of 2026-11-07
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4bedd21-efde-44c6-9d9c-b48b78d7ed1e
Lenvima (lenvatinib) USPI, DailyMed setid f4bedd21-efde-44c6-9d9c-b48b78d7ed1e, published 10.22.2026, re-opened 2026-10-27 (raw/dailymed/lenvima.txt). The label has no adenoid cystic carcinoma indication (text search, 0 hits). Safety figures used are from other cancers (SELECT thyroid: dose reductions 68%, discontinuation for adverse reactions 18%) and are class context only.
Brief source A1
publication, as of 2026-11-07
https://pubmed.ncbi.nlm.nih.gov/30939095/
Ho AL et al. Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma, J Clin Oncol 2019, doi 10.1200/JCO.18.01859, PMID 30939095 (publication abstract; opened 2026-10-27): 33 enrolled, 32 evaluable; 24 mg daily; 5 partial responses (15.6%), 24 stable disease; median PFS 17.5 months (95% CI 7.2 to not reached; only 8 progression events); 23 patients needed at least one dose modification; 18 of 32 discontinued for drug-related issues; grade 3 or 4 hypertension 28.1%, oral pain 9.4%; three grade 4 events.
Brief source A19
publication, as of 2026-11-07
https://pubmed.ncbi.nlm.nih.gov/32031693/
Locati LD et al. ACC-LEN14, lenvatinib in R/M salivary ACC, Cancer 2020, PMID 32031693 (publication abstract; opened 2026-10-27): 28 enrolled, 26 evaluable, 3 partial responses (11.5%); grade 3 or higher TRAEs 50%; dose reduced in 24 patients; median PFS 9.1 months, OS 27 months, DoR 3.1 months; quality of life deteriorated for fatigue and dry mouth at 6 months, with no change in swallowing or physical functioning. Italian real-world series (Head and Neck 2025, PMID 40033633, abstract opened): 51 patients, ORR 21.7%, grade 3 or higher hypertension 25.5%, stomatitis 17.6%, median OS 16.1 months.
Brief source A20
publication, as of 2026-11-07
https://doi.org/10.1200/jco.2023.41.16_suppl.6048
Lenvatinib plus pembrolizumab in progressive R/M ACC, ASCO 2023 abstract 6048 (doi 10.1200/jco.2023.41.16_suppl.6048; abstract not opened; figures from a search record): 17 evaluable, ORR 6% (1 partial response), below the prespecified threshold; 76% stable disease; grade 3 or higher toxicity 71%. Registry NCT04209660 still active, not recruiting, PCD 2026-12.
Brief source A25
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT02780310
A Phase II Study of Lenvatinib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT02860936
Phase II Study on Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands of the Upper Aerodigestive Tract
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT04209660
A Phase II Study of Lenvatinib Plus Pembrolizumab in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
ClinicalTrials.gov API v2 record, retrieved 2026-11-07